Lyell Stock

lyellbiotech.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $1.04B

Lyell Immunopharma is a developer of curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors.

Register To Buy and Sell Shares

For more details on financing and valuation for Lyell, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Lyell’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Lyell.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Premal Patel MD
Chief Medical Officer
Akira Matsuno
Chief Financial Officer & Head of Corporate Development
Richard Klausner MD
Founder, President, Board Member & Chief Executive Officer

Board Members

Richard Klausner MD
Robert Nelsen
ARCH Venture Partners
Cathy Friedman
Hans Bishop
Updated on: Apr 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.